Humana expands GLP-1 cost-control program with employers for 2027 benefit year

Humana is scaling a new cost-linked program with employers to manage GLP-1 agonist drug benefits, set to be offered for the 2027 plan year. The program structures coverage and reimbursement around negotiated pricing tiers, including options for brand-name versus compounded semaglutide and tirzepatide. This follows Humana's Q2 earnings announcement where it cited pharmacy cost management as a core 2027 strategy. For practices, this signals that employer-sponsored Humana plans will likely introduce new prior-auth criteria, step-therapy requirements, or preferred pharmacy networks for weight-loss and diabetes drugs starting January 2027. Anticipate increased administrative burden for securing GLP-1 approvals under Humana commercial plans. Review Humana's 2027 provider policy bulletins when released in November 2026 to understand the new medical-necessity forms and documentation requirements.